Indiscreet Prescribing Of Antibiotics Cause Of Microbial Resistance Minister In RS

New Delhi: Indiscreet prescribing of antibiotics is one of the major causes of microbial resistance in the country, Minister of State for Health S P Singh Baghel told Rajya Sabha on Tuesday.

The National Centre for Disease Control (NCDC) conducted a point prevalence survey (PPS) on antibiotic use at 20 tertiary care government hospitals (NAC-NET sites).

This study was conducted amongst 9,653 eligible patients admitted to these 20 hospitals, Baghel said in a written reply.

The survey found that 71.9 per cent of the patients received antibiotics.

Of those who were prescribed antibiotics, 54.8 per cent received antibiotics for prophylactic indications (surgical prophylaxis 37.3 per cent and medical prophylaxis 17.5 per cent).

“Indiscreet prescribing of antibiotics is one of the major causes of microbial resistance in the country,” he said.

The Union health ministry has initiated several initiatives to promote judicious use of antimicrobials.

The ministry launched the Red Line awareness campaign on antimicrobial resistance, urging people not to use medicines marked with a red vertical line, including antibiotics, without a doctor’s prescription.

The Indian Council of Medical Research (ICMR) has released treatment guidelines for antimicrobial use in common syndromes in which guidelines for the use of antibiotics for viral bronchitis and low-grade fever antibiotics are included in Schedule H and H1 of the Drugs Rules, 1945.

These drugs have specific caution labelling requirements and are sold only under the prescription of a registered medical practitioner.

The supply of a drug specified in Schedule H1 is recorded in a separate register and such records, which are maintained for three years, are open for inspection.

The Central Drugs Standard Control Organisation (CDSCO) has placed 24 hi-end antimicrobials under schedule H1 by issuing notification, Baghel stated.

Related Posts

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?